Breaking News, Trials & Filings

Idorsia’s TRYVIO Approved by FDA for the Treatment of Hypertension

Idorsia plans to make TRYVIO available to the millions of patients in the US who are not controlled on other drugs in the second half of 2024.

Author Image

By: Charlie Sternberg

Associate Editor

The US Food and Drug Administration (FDA) has approved Idorsia Ltd.’s TRYVIO (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.   Jean-Paul Clozel, MD and CEO of Idorsia commented, “Today, there are millions of Americans whos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters